509 Hale Street
About Amygdala NeurosciencesAmygdala Neurosciences is a biopharmaceutical company focused on the development and commercialization of first-in-class drug candidates for the treatment of addiction disorders. Amygdala was founded and is led by industry leaders and therapeutic experts who include: Executive Chairman Lou Lange, MD, PhD; Chief Science Officer Ivan Diamond, MD, PhD; President and Chief Executive Officer Peter Strumph; and Chief Financial Officer Adrienne MacMillan.
Executive Chairman and Founder: Lou Lange, MD, PhD
President, CEO and Founder: Peter Strumph
Founder and CSO: Ivan Diamond, MD, PhD
Founder and CFO: Adrienne MacMillan
Please click here for Amygdala Neurosciences' technology.
8 articles with Amygdala Neurosciences
Funds will support current and planned Phase 2 clinical studies to assess ANS-6637 as a treatment for opioid, alcohol, and smoking/nicotine use disorders
Amygdala Neurosciences Awarded $1.35 million NIH Grant to Conduct Long Term, Phase 3 Enabling, Toxicology Studies
ANS-6637, which is in Phase 2 clinical development, is a new chemical entity selective ALDH2 Inhibitor with a mechanism of action expected to prevent craving and relapse for patients being treated for substance use disorders.
Amygdala Neurosciences Announces Dosing of the First Patient in the NIH Funded Phase 2 Proof-Of-Concept study of ANS-6637 for the Treatment of Alcohol Use Disorder
ANS-6637 is a new chemical entity selective ALDH2 Inhibitor with a mechanism of action expected to prevent craving and relapse for patients being treated for substance use disorders including alcohol use disorder.
Amygdala Neurosciences Announces Dosing the First Patients in the $12.4 Million NIH HEAL Initiative Funded SEARCH Program of Clinical Studies with ANS-6637
Amygdala Neurosciences (a private company) announced today the start of dosing in a NIH/NIAID Phase 1b study to test the safety of ANS-6637, and how it effects the processing of drugs such buprenorphine that are processed by the same liver enzyme pathway.
Amygdala Neurosciences Announces the $12.4 Million HEAL Initiative Sponsored SEARCH (Safety and Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People with Opioid Use Disorder) Program of Phase 2 Clinical Studies
Amygdala Neurosciences (a private company) announced today the SEARCH program of Phase 2 clinical studies which are sponsored by the National Institute of Allergy and Infectious Diseases (NIAID, a division of NIH) and are being conducted by the NIH Clinical Center and the Institute of Human Virology (IHV) at the University of Maryland School of Medicine.
Amygdala Neurosciences and NIAAA will Conduct a Phase 2 Clinical study of ANS-6637 for the Treatment of Alcohol Use Disorder
Amygdala Neurosciences (a private company) announced today that the National Institute on Alcohol Abuse and Alcoholism (NIAAA, a division of NIH) will fund and conduct a Phase 2, human laboratory study of ANS-6637 for the treatment of alcohol use disorder.
Amygdala Initiates Phase Ib Clinical Study Of ANS-6637, The First-In-Class Selective ALDH2 Inhibitor In Development As A Treatment For Substance Use Disorder